PTO/SB/ST (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/805,788 म्रोRANSMITTAL 2 2 2007 Filing Date Mar 22, 2004 AL **FORM** First Named Inventor Quay, Steven C. STER Art Unit 1654 used for all correspondence after initial filing) **Examiner Name** Thomas Sweeney Heard Total Number of Pages in This Submission Attorney Docket Number 03-04US **ENCLOSURES** (Check all that apply) After Allowance communication to (TC) Fee Transmittal Form Drawing(s) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment / Reply Petition (Appeal Notice, Brief, Reply Brlef) Petition to Convert to a After Final **Proprietary Information** Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please identify **Extension of Time Request** Terminal Disclaimer below): Form SB08a - page two with correction **Express Abandonment Request** Request for Refund in red Information Disclosure Statement -CD, Number of CD(s) Substitute page 2 only Landscape Table on CD Certified Copy of Priority Document(s) Remarks Reply to Missing Parts/ Incomplete Application On August 19, 2005, we filed a three-page IDS. We noted a typographical error on the first line of the "U.S. Patent Documents" section. The Takeda Chemical Reply to Missing Parts under Industries (corrected from Coflexip) U.S. Patent Number has been corrected from 37 CFR 1.52 or 1.53 5,428,706 to the correct patent number of 5,482,706. Please switch out the prior page two for this new page two. Thank you. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Nastech Pharmaceutical Company Inc. Signature Printed name Peter . Knudsen Date 40682 January 18, 2007 Reg. No. CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below Signature Typed or printed name Date January 18, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## JAN 2 2 2007 BU

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicants: Quay et al.

Serial No.: 10/805,788

Filed: 3/22/2004

Title: NASAL CALCITONIN

FORMULATIONS CONTAINING

CHLOROBUTANOL

Assignee: Nastech Pharmaceutical Company

Inc. by Reel 014824 /Frame 0710

Group Art Unit: 1654

Examiner: Thomas Sweeney Heard

Attorney Docket No.: 03-04US

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUBSTITUTE INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith a substitute Form PTO SB08a-Information Disclosure Statement by Applicant-page two only, to correct a typographical error on a U.S. patent number and name of Applicant cited.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the correspondence is being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit:

Typed Name: Kerry King

Signature:

Peter J. Knudsen

Attorney for Applicants

Nastech Pharmaceutical Company Inc.

3830 Monte Villa Parkway Bothell, WA 98021-7266

(425) 908-3643 phone

(425) 908-3653 fax

pknudsen@nastech.com

Reg. No.: 40,682

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STEW

Signature

* TRADES					Complete if Known					
Substitute for form 1449A/PTO					Application Number		10/80	10/805,788		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date		3/22/2	3/22/2004		
					First Named Inventor		Quay	Quay et al.		
							1614			
(Use as many sheets as necessary)					Examiner Name					
Sheet	1	2	of 3		Attorney Docket Number 03-04		us			
Officer	-1		<del></del>	ATENT			7 00 0 1			
		Document Number Publication			Name of Patentee or			Pages, Columns, Lines, Where		
Examiner Initials*	Cite No.1	Number - Kir@Code <sup>2 (if known)</sup>	MM-DD-Y		Applicant of Cited Docume			Relevant Passages or Releva Figures Appear	nt	
		US-5,428,708 5 US 2 1/L	Issued 6-27-	-1995	Coflexi	Taked Chemic		d Industries, lac		
		US-5,482,931	Issued 01-09-1996		Ferring AB			21. 20.2(1.40) 40.0	<u> </u>	
		US-5,503,827	Issued 04-02-1996		Boehringer Mannheim GmbH		mbH			
		US-5,508,260	Issued 04-16-1996		Amylin Pharmaceuticals, Inc.		Inc.			
····		US-5,514,365	Issued 05-0		Schiapparelli Salute S.P.A.					
·		US-5,527,771	Issued 06-18	8-1996		n Pharmaceuticals, Inc.				
) <del>/     </del>		US-5,554,378	Issued 09-10	0-1996		a Chemical Industries,				
······		US-5,565,423	Issued 10-1	5-1996	Hoechs	chst Aktiengesellschaft				
		US-5,574,006	Issued 11-12		Dott Research Laboratory					
		US-5,576,016	Issued 11-19	9-1996	Pharmos Corporation					
)		US-5,578,324	Issued 11-26-199		Teijin Limited					
	·	US-5,603,943	Issued 02-18-1997		Dott Research Laboratory					
( <del>*********************************</del>	·	US-5,654,000	Issued 08-05-1997		Poli Industria Chimica S.p.Al					
,		US-5,681,811	Issued 10-28-1997		Protein Delivery, Inc.					
		US-5,693,608	Issued 12-02-1997		Bechgaard International Research and Development					
	·····	US-5,719,122	Issued 02-17-1998		SmithKline Beecham Farmaceutici S.p.A.					
)		US-5,725,852	Issued 03-10-1998		Takeda Chemical Industries,					
		US-5,725,871	Issued 03-10-1998		Danbiosyst UK Limited					
		US-5,733,569	Issued 03-3		Novartis Corporation					
			FOREIG	N PATEN	T DOCU	MENTS				
		Foreign Patent Document			ation Date Name of Patent			Pages, Columns, Lines,		
Examiner Initials*	Cite No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Cod			on Date Name of Patente Name of Patente Applicant of Cited De			t Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
		GB 2 177 914 A			987	Chugai Seiyaku				
		EP 0 358 234 A2		03-14-1990		Chugai Seiyaku Kabushiki Kaisha Rorer International (Overseas) Inc.		HILLER CONTROL	-	
		EP 0 371 010 A1		05-30-1	990	Yamanouchi				
		EP 0 418 697 A1	······	03-27-1	991	Pharmaceutical Co. Ltd Esseit s.a.s. Laboratoric Chimico Farmaco Biologico Di A. levoli & C			-	
		EI 0410 037 A1		03-27-1	1001					
		EP 0 471 618 A1		08-12-1991		Toyo Jozo Co., Ltd.				
		EP 0 489 217 A1		06-10-1992		DR. A Tosi Farmaceutici S.R.L.				
						- annaveullo S	171-1	<u></u>		
Examiner						Date				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Considered

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known						
obstitute for form 1445/97 TO						Application Number		10/805,788			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing D	ng Date 3/22/200		/2004			
						First Named Inventor Quay et		et al.			
					Art Unit						
(Use as many sheets as necessary)					er Name	1654 Thomas	Sweeney Heard				
Sheet		2	of 3	3	Attorne	Docket Number	03-04US	3			
U.S. PATENT DOCUMENTS											
Evenines	Cita	Document Number	Publication	Date	Name of Patentee or			Pages, Columns, Lines, Wi			
Examiner Initials*	Cite No.1	Number - Kind Code <sup>2 (if known)</sup>	MM-DD-Y	MM-DD-YYYY		plicant of Cited Doo	Relevant Passages or Relevant Figures Appear				
		US-5,482,706	Issued 6-27-1995		Takeda Chemical Industries, Ltd.						
		US-5,482,931	Issued 01-09-1996		Ferring AB						
		US-5,503,827	Issued 04-02-1996		Boehringer Mannheim GmbH						
		US-5,508,260	Issued 04-16-1996		Amylin Pharmaceuticals, Inc.						
)		US-5,514,365	Issued 05-07-1996		Schiapparelli Salute S.P.A.				***************************************		
		US-5,527,771	Issued 06-18-1996		Amylin Pharmaceuticals, Inc.						
		US-5,554,378	Issued 09-10-1996		Takeda Chemical Industries, Ltd.						
		US-5,565,423	Issued 10-15-1996		Hoechst Aktiengesellschaft				***************************************		
		US-5,574,006	Issued 11-12-1996		Dott Research Laboratory			<u> </u>			
)- <u>trium-man-man-man-man-man-</u>		US-5,576,016	Issued 11-19-1996		Pharmos Corporation						
		US-5,578,324	Issued 11-19-1996		Teijin Limited						
		US-5,603,943	Issued 02-18-1997 Issued 08-05-1997		Dott Research Laboratory Poli Industria Chimica S.p.A.				***************************************		
		US-5,654,000									
		US-5,681,811	Issued 10-28-1997		Protein Delivery, Inc.						
		US-5,693,608	Issued 12-02-1997 Issued 02-17-1998		Bechgaard International Research and Development A/S SmithKline Beecham Farmaceutici S.p.A.			1			
		00 0,000,000									
		US-5,719,122									
)· <u></u>		1.0 - 70- 0-0									
)·····		US-5,725,852	Issued 03-10-1998		Takeda Chemical Industries, Ltd.  Danbiosyst UK Limited						
)		US-5,725,871	Issued 03-10-1998				<del>,</del>				
		US-5,733,569	Issued 03-31-1998		Novartis Corporation			i			
			FOREIG	N PATE	IT DOCU	MENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Docum  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Cod		ion Date D-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳			
		GB 2 177 914 A		02-04-	1987 Chugai Seiyaku Kabushiki Kaisha						
		EP 0 358 234 A2		03-14-	1990	990 Rorer Internationa (Overseas) Inc.					
		EP 0 371 010 A1		05-30-	1990	Yamanouchi Pharmaceutica	Co. Ltd		-		
	<b></b>	EP 0 418 697 A1		03-27-	1991	Esseit s.a.s. La			1		
						Chimico Farmaco Biologico Di A. Ievoli & C.					
		EP 0 471 618 A1		08-12-	1991	Toyo Jozo Co.,			1		
		EP 0 489 217 A1		06-10-1992		DR. A Tosi Fa S.R.L.	maceutici				
Examiner						Date					

Signature Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



This return receipt postcard acknowledges receipt by the U.S.

Patent Office of the following: U.S. Utility patent

Application Serial No. 10/805,788:

Title: NASAL CALCITONIN FORMULATIONS

CONTAINING CHLOROBUTANOL

Inventors: Steven C. Quay, et. al.

Mailed to the Commissioner for Patents: 3/22/2004

X Substitute Information Disclosure Statement

X PTO Form SB08a – substitute page 2, plus copy of original with correction in red

X Transmittal Form

Attorney Docket No.: 03-04US, Project 0130